SYK · Q4 2025 Earnings

Narrative arc: Q2 FY25 (first raise, tariffs bounded) → Q3 FY25 (second raise, tariff burden up, EPS resilience) → Q4 FY25 (FY beat, FY26 normalization with tariff load doubling) → FY26 (margin engine declared structural).

Tariff framing moved from in-period burden to embedded multi-year cost structure. Three quarters ago tariffs were a swing variable being managed down ($200M → $175M in Q2); two quarters ago the FY25 figure went back up to ~$200M with FX-dependent conditional framing; this quarter management quantifies FY26 tariffs at ~$400M with $200M incremental and explicitly H1-weighted. The shift is from headwind-being-absorbed to baseline-cost-of-doing-business — and the EPS guide of +9.4 to +10.8% YoY clears that doubled load without flinching. "We expect full-year tariff impacts to be approximately $400 million, which includes an incremental $200 million compared to 2025." The disclosure precision is itself the tone signal.

Mako language escalated from category leader to dominant strategic engine. Q2 FY25 framed Stryker as "clear leader in orthopedic robotics"; Q3 FY25 cited record installs and a software refresh; this quarter management used "stunning" — a word notably absent from prior Stryker prints — to describe Mako 4 installs, paired with the disclosure that US Mako penetration crossed two-thirds of knees and one-third of hips, with shoulder launching on Mako 4 mid-2026. "Powered by Mako 4, we delivered a stunning quarter and year of Mako installations with yet another record quarter, both in the US and worldwide." The escalation from "leader" to "stunning" with explicit platform-extension roadmap reframes Mako from product category to multi-year compounding flywheel.

Margin expansion language hardened from achievement to structural capability. Q2 FY25 framed +100bps as the committed target; Q3 FY25 sharpened to "firmly on track" with "conviction"; this quarter the framing is "a second consecutive year of at least 100 basis points of adjusted operating margin expansion" paired with a return to pre-COVID adjusted operating margins and explicit reaffirmation of the 150bps-through-2028 trajectory. The language moved from delivering-the-number to operating-the-machine — Preston's framing of operational excellence, lean, and shared services as the engine puts margin expansion in the recurring-capability bucket, not the cyclical-leverage bucket.

Supply constraints retired as a named risk for FY26. Q3 FY25 still referenced ongoing Medical division supply disruption "continuing all year"; this quarter management explicitly removed the line item from FY26 risk: "We do not expect the supply constraints we experienced in 2025 to negatively impact growth rates in 2026." That is an unhedged statement and a material assumption underneath the 8–9.5% organic guide — if supply doesn't return as a headwind, the guide carries upside.

Organic growth guidance narrowed and reframed as deliberate. Last year's initial FY25 guide began at 8–9% before being raised twice to 9.8–10.2% and ultimately delivered at 10.3% organic. The FY26 starting range of 8.0–9.5% is structurally similar to where FY25 began, but management framed the deceleration as positioning at the "high end of MedTech" rather than apologizing for it. The implication: management is signaling confidence the same pattern (initial guide → multiple raises) can repeat, while embedding $200M of incremental tariff in the starting algorithm.